NEWS
  • Jun 30, 2015

    Eolas Therapeutics and AstraZeneca Partner to Develop Orexin-1 Receptor Antagonist for Multiple Indications

    Eolas Therapeutics, Inc. announced today that is has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications…. MORE >

  • 02 July 2015

    Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease

    Parkinson’s disease is the second most common chronic neurodegenerative disorder. Most symptomatic treatments for Parkinson’s disease target the dopamine system and provide symptom relief in early to intermediate stages… MORE>

  • September 16th 2014

    AstraZeneca and Lilly announce alliance to develop and commercialize BACE inhibitor AZD3293 for Alzheimer’s disease

    AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease… MORE>

  • May 2014

    NCATS Announces Funding Opportunities to Repurpose Drug Candidates from Industry

    NCATS now is accepting applications for its Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program. Today, NCATS issued funding announcements and provided information about partially developed therapeutic candidates — referred to as “agents” — for researchers to crowdsource ideas for new uses. Launched in 2012 as a pilot initiative, New Therapeutic Uses matches researchers with a selection of pharmaceutical industry agents to explore new treatments for patients… MORE>